FDA OKs first human FDA OKs trial of oral MS remyelination therapy PTD802

Article

Many with MS hope for a cure or a treatment that repairs the myelin sheath. There have been peptide patches and other treatments suggested for this myelin repair.

Summary of the article:

• The FDA has approved the first-in-human trial testing PTD802, an oral remyelination therapy for multiple sclerosis by pheno Therapeutics.
• The treatment is designed to boost repair of myelin, which is the protective coating surrounding nerve fibers.
• This treatment aims to restore lost function for people with MS and other neurological conditions.